Related Experiment Video
Updated: Aug 1, 2026
10:52
Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
Published on: March 30, 2018
[MALT-lymphoma]
1Medizinische Klinik, GP-Klinikum Rüsselsheim. d.flieger@gp-ruesselsheim.de
Praxis
|August 17, 2006
Summary
Gastric MALT lymphoma is often caused by Helicobacter pylori infection, treatable with antibiotics. Further treatment options for refractory cases include radiotherapy, chemotherapy, or surgery, with rituximab showing promise.
Area of Science:
- Gastroenterology and Oncology
- Immunology
Background:
- Gastric lymphoma is predominantly extranodal marginal zone-B-cell-lymphoma of mucosa-associated lymphoid tissue (MALT).
- Helicobacter pylori infection is a newly identified cause of gastric MALT lymphomas.
- Diagnosis relies on tumor biopsy, with staging utilizing imaging techniques like CT, endosonography, and capsule endoscopy.
Purpose of the Study:
- To summarize the current understanding and treatment of gastric lymphomas.
- To highlight the role of Helicobacter pylori in MALT lymphoma development.
- To discuss therapeutic strategies including antibiotic eradication, conventional treatments, and novel approaches.
Main Methods:
- Review of diagnostic modalities for gastric lymphoma.
- Analysis of treatment outcomes for MALT and aggressive gastric lymphomas.
- Evaluation of Helicobacter pylori eradication as a primary treatment strategy.
Main Results:
- Antibiotic eradication of Helicobacter pylori offers a breakthrough, side-effect-poor treatment for MALT lymphomas.
- Refractory MALT lymphomas can be managed with radiotherapy, chemotherapy, or surgical resection.
- Aggressive gastric lymphomas are primarily treated with chemotherapy and radiotherapy.
Conclusions:
- Helicobacter pylori eradication is a key therapeutic advance for gastric MALT lymphoma.
- Conventional treatments remain options for refractory MALT lymphomas and aggressive lymphomas.
- Monoclonal antibody therapy, such as rituximab targeting CD20, may improve outcomes in ongoing clinical trials.
